Stampacchia Otello 4
4 · Ikena Oncology, Inc. · Filed Apr 1, 2021
Insider Transaction Report
Form 4
Stampacchia Otello
Director
Transactions
- Award
Series B Preferred Stock
2020-12-21$1.40/sh+12,870,933$18,000,000→ 12,870,933 total(indirect: By Omega Fund VI, L.P.)→ Common Stock (1,799,123 underlying) - Conversion
Common Stock
2021-03-30+1,799,123→ 1,799,123 total(indirect: By Omega Fund VI, L.P.) - Conversion
Series B Preferred Stock
2021-03-30−12,870,933→ 0 total(indirect: By Omega Fund VI, L.P.)→ Common Stock (1,799,123 underlying) - Award
Common Stock
2021-03-30$16.00/sh+450,000$7,200,000→ 2,249,123 total(indirect: By Omega Fund VI, L.P.)
Footnotes (3)
- [F1]Each share of Series B Preferred Stock (the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
- [F2]Shares held directly by Omega Fund VI, L.P. ("Omega VI"). Omega Fund VI GP, L.P. ("Omega VI GP") is the sole general partner of Omega VI. Omega Fund VI GP Manager, Ltd. ("Omega VI Manager") is the sole general partner of Omega VI GP. The Reporting Person is a director of Omega VI Manager and disclaims beneficial ownership of the shares held by Omega VI except to the extent of his pecuniary interest therein, if any.
- [F3]This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.